Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies
US-2016311908-A1 · Oct 27, 2016 · US
Platform for T lymphocyte genome engineering and in vivo high-throughput screening thereof
US11926839B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11926839-B2 |
| Application number | US-201816605715-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 17, 2018 |
| Priority date | Apr 18, 2017 |
| Publication date | Mar 12, 2024 |
| Grant date | Mar 12, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention includes compositions and methods for T cell genome editing and screening in vivo. In certain aspects, the invention includes an sgRNA library for genome-scale mutagenesis.
First claim
Opening claim text (preview).
What is claimed is: 1. A vector comprising a 5′ long terminal repeat (LTR) sequence, a U6 promoter sequence, a BsmB1 restriction site, an EFS sequence, an sgRNA expression cassette, a Thy1.1 cassette, a 3′ LTR sequence and an ampicillin a resistance gene sequence (AmpR) wherein the vector comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 129,213, SEQ ID NO: 129,214, and SEQ ID NO: 129,215. 2. A vector comprising a 5′ long terminal repeat (LTR) sequence, a U6 promoter sequence, a BsmB1 restriction site, an EFS sequence, an sgRNA expression cassette, a Thy1.1 cassette, a 3′ LTR sequence and an ampicillin resistance gene sequence (AmpR), wherein the sgRNA expression cassette expresses an sgRNA comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-129,209. 3. The vector of claim 2 , wherein the sgRNA expression cassette expresses an sgRNA consisting of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-129,209.
Assignees
Inventors
Classifications
Cancer antigens · CPC title
T-cell receptors [TCR] · CPC title
T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title
Breast · CPC title
characterised by the dose, timing or administration schedule · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11926839B2 cover?
- The present invention includes compositions and methods for T cell genome editing and screening in vivo. In certain aspects, the invention includes an sgRNA library for genome-scale mutagenesis.
- Who is the assignee on this patent?
- Univ Yale
- What technology area does this patent fall under?
- Primary CPC classification C12N15/85. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).